{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=31", "query": { "intervention": "capecitabine", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 760, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=capecitabine&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T20:15:30.668Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00642603", "title": "A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2008-05", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 76, "location_summary": "PARK Springs, Arizona • Sedona, Arizona • Tucson, Arizona + 68 more", "locations": [ { "city": "PARK Springs", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642603" }, { "nct_id": "NCT00452673", "title": "Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2007-06", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2015-03-24", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 4, "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452673" }, { "nct_id": "NCT00717197", "title": "Study of Capecitabine to Treat Recurrent High Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-07", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2013-07-02", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00717197" }, { "nct_id": "NCT06469944", "title": "Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Junction", "Gastroesophageal Adenocarcinoma", "Esophageal Neoplasms", "Esophageal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab Tirumotecan (sac-TMT)", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Patritumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2024-09-20", "completion_date": "2029-09-12", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 8, "location_summary": "Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06469944" }, { "nct_id": "NCT04456699", "title": "Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin/ levoleucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2020-08-19", "completion_date": "2023-11-06", "has_results": true, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 23, "location_summary": "Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04456699" }, { "nct_id": "NCT01459614", "title": "Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Taxotere", "type": "DRUG" }, { "name": "Xeloda", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 44, "start_date": "2011-11", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01459614" }, { "nct_id": "NCT00216021", "title": "Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoosier Cancer Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2004-03", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2015-12-09", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 11, "location_summary": "Newark, Delaware • Galesburg, Illinois • Elkhart, Indiana + 6 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216021" }, { "nct_id": "NCT00077077", "title": "DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "DJ-927", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2004-02", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Detroit, Michigan • San Antonio, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Detroit", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077077" }, { "nct_id": "NCT00095901", "title": "Capecitabine For Nasopharyngeal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2004-06", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 3, "location_summary": "Chicago, Illinois • Boston, Massachusetts", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095901" }, { "nct_id": "NCT02024607", "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Gastrointestinal Cancer" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 495, "start_date": "2014-01", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2023-11-15", "last_synced_at": "2026-10-29T20:15:30.668Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02024607" } ] }